Economics, Pharmaceutical
"Economics, Pharmaceutical" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Economic aspects of the fields of pharmacy and pharmacology as they apply to the development and study of medical economics in rational drug therapy and the impact of pharmaceuticals on the cost of medical care. Pharmaceutical economics also includes the economic considerations of the pharmaceutical care delivery system and in drug prescribing, particularly of cost-benefit values. (From J Res Pharm Econ 1989;1(1); PharmacoEcon 1992;1(1))
Below are MeSH descriptors whose meaning is more general than "Economics, Pharmaceutical".
Below are MeSH descriptors whose meaning is more specific than "Economics, Pharmaceutical".
This graph shows the total number of publications written about "Economics, Pharmaceutical" by people in Harvard Catalyst Profiles by year, and whether "Economics, Pharmaceutical" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 0 | 1 | 1 |
| 1994 | 0 | 2 | 2 |
| 1995 | 0 | 1 | 1 |
| 1997 | 2 | 0 | 2 |
| 1999 | 0 | 4 | 4 |
| 2000 | 1 | 0 | 1 |
| 2001 | 1 | 2 | 3 |
| 2002 | 0 | 2 | 2 |
| 2003 | 1 | 4 | 5 |
| 2004 | 3 | 0 | 3 |
| 2005 | 1 | 1 | 2 |
| 2006 | 1 | 1 | 2 |
| 2007 | 1 | 0 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 3 | 0 | 3 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 3 | 3 | 6 |
| 2013 | 1 | 0 | 1 |
| 2014 | 0 | 2 | 2 |
| 2015 | 0 | 2 | 2 |
| 2016 | 3 | 1 | 4 |
| 2017 | 5 | 1 | 6 |
| 2018 | 2 | 1 | 3 |
| 2020 | 4 | 4 | 8 |
Below are the most recent publications written about "Economics, Pharmaceutical" by people in Profiles.
-
Improving transparency to build trust in real-world secondary data studies for hypothesis testing-Why, what, and how: recommendations and a road map from the real-world evidence transparency initiative. Pharmacoepidemiol Drug Saf. 2020 11; 29(11):1504-1513.
-
Comparing Onset of Biosimilar Versus Generic Competition in the United States. Clin Pharmacol Ther. 2020 12; 108(6):1308-1314.
-
Differential Index-Hospitalization Cost Center Impact of Enhanced Recovery After Surgery Program Implementation. Dis Colon Rectum. 2020 06; 63(6):837-841.
-
We are Not Meeting the Needs of Pharmacoeconomic Models of Nonalcoholic Steatohepatitis, But We Can. Pharmacoeconomics. 2020 05; 38(5):427-429.
-
Dissecting drug pricing: Supply chain, market, and nonmarket trends impacting clinical dermatology. J Am Acad Dermatol. 2020 08; 83(2):691-699.
-
Being Precise About Precision Medicine: What Should Value Frameworks Incorporate to Address Precision Medicine? A Report of the Personalized Precision Medicine Special Interest Group. Value Health. 2020 05; 23(5):529-539.
-
Transferability of Economic Evaluations of Treatments for Advanced Melanoma. Pharmacoeconomics. 2020 02; 38(2):217-231.
-
Grounding Value-Based Drug Pricing in Population Health. Clin Pharmacol Ther. 2020 06; 107(6):1290-1292.
-
Pharmacoeconomic analysis of antibiotic therapy in surgical site infections?. Int J Clin Pharmacol Ther. 2019 Sep; 57(9):429-436.
-
Pre-Nusinersen Hospitalization Costs of Children With Spinal Muscular Atrophy. Pediatr Neurol. 2019 03; 92:3-5.